Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Elsevier Offers Free Content for Rare Disease Day

This image opens in the lightbox

News provided by

Elsevier

26 Feb, 2020, 15:39 GMT

Share this article

Share toX

Share this article

Share toX

Starting February 29, 2020, Elsevier will make clinical review articles and book chapters openly accessible for 60 days to raise awareness of rare diseases

NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Elsevier, a global leader in information analytics, specializing in science and health, is making clinical review articles and book chapters on rare and undiagnosed diseases free for 60 days beginning on Rare Disease Day (#RareDiseaseDay), February 29, 2020. The free content consists of clinical review articles and book chapters intended to support new research and treatment and to raise awareness around rare diseases.

Rare Disease Day improves knowledge amongst the general public of rare diseases, while supporting researchers, clinicians, public authorities, industry representatives and other decision makers in addressing the needs of those living with rare diseases1. There are approximately 7,000 known rare diseases, and roughly 300 million people worldwide suffer from one of these diseases2,3. Rare disease symptoms range widely from disease to disease, and even from person to person, making diagnosis and treatment difficult. Today, 95 percent of rare diseases still lack an FDA approved treatment and research funding is scarce compared to funding for common disease research4. Those affected by rare disease often face challenges searching for a diagnosis, finding the information they need and gaining access to quality health care. Meanwhile, these individuals remain socially, economically and culturally vulnerable5.

Since Rare Disease Day was first launched by EURORDIS (European Organization for Rare Diseases) and its Council of National Alliances in 2008, thousands of rare disease events have taken place throughout the world, reaching hundreds of thousands of people. Its website provides information about local and worldwide events. In an effort to support its clinical and scientific audiences globally, Elsevier's Education, Reference, and Continuity group is participating in this year's events by opening up access to highly utilized content–from book chapters to clinical review articles–on rare diseases.

This content supports researchers and clinicians in identifying the molecular basis of these diseases, advancing drug discovery and drug repurposing efforts, translating findings to the clinic, and counseling patients and families. Leading articles from Elsevier's Clinics volumes detail a range of specific diseases, from rare mitochondrial disease to autoimmune disorders. The general public, policy makers and administrators will also find information on the challenges of living with rare disease, economic costs and social aspects of rare disease. 

"Diagnosis, patient care, and long-term management of patients with any of these 7,000 rare diseases can be confounding. In offering this content, we hope to reinforce our commitment to supporting rare disease communities and individuals with rare disease, advancing rare disease research and empowering medical practice in this area," said Laura Colantoni, Vice President, Reference Content, Elsevier.

Please see the links below to freely access these chapters and articles through April 30, 2020. Access to the promotion of these articles and chapters can also be found on Elsevier's Twitter accounts, and access to worldwide promotion of this event can be found via #RareDiseaseDay on February 29, 2020.

To view clinical review articles in specific specialties, visit Elsevier's Clinics Review Articles. To browse book content in this area, visit Elsevier Life Sciences and Elsevier Health.

Free content

Background, from Jules Berman, Rare Diseases and Orphan Drugs (First Edition):

Chapter 1 - What are the Rare Diseases, and Why do we Care?

Chapter 3 - Six Observations to Ponder while Reading this Book

Chapter 8 - Cancer (Rare and Common Cancers)

Chapter 9 - Causation and the Limits of Modern Genetics

Chapter 10 - Pathogenesis: Causation's Shadow

Chapter 11 - Rare Diseases and Common Diseases: Understanding their Fundamental Differences

Chapter 12 - Rare Diseases and Common Diseases: Understanding their Relationships

Chapter 13 - Shared Benefits

Genetic Testing:

Chapter 4 - Genetic Testing for Rare and Undiagnosed Diseases, Thomas Morgan, Genomic and Precision Medicine: Primary Care (Third Edition)

Society and Public Health:

Chapter 10 - The "Life Costs" of Living with Rare Genetic Diseases, Koichi Mikami, Alastair Kent, Gill Haddow, Genomics and Society (First Edition)

Chapter 3 - Rare Diseases: Genomics and Public Health, Gabriela M. Repetto, Boris Rebolledo-Jaramillo, Applied Genomics and Public Health (First Edition):

Clinical Review Articles and Textbook Chapters:

Armangue T and Dalmauln JO. Autoimmune Encephalitis. In: Kliegman RM, and St. Geme JW, eds. Nelson Textbook of Pediatrics, 21st edition.  Philadelphia, PA: Elsevier; 2020.

Verbsky JW. Hereditary Periodic Fever Syndromes and Other Systemic Autoinflammatory Diseases. In: Kliegman RM, and St. Geme JW, eds. Nelson Textbook of Pediatrics, 21st edition.  Philadelphia, PA: Elsevier; 2020.

Stankovits LM, Lopyan AH: Genetic and Metabolic Conditions. Pediatric Clinics of North America, 67:1, 2019

Haralur Y, Mechtler LL: Neuroimaging of Multiple Sclerosis Mimics. Neurologic Clinics 38:1, 2020.

Ly KA, Blakely JO: The Diagnosis and Management of Neurofibromatosis Type 1. Medical Clinics of North America  103:6, 2019.  

Reich SG : Does This Patient Have Parkinson Disease or Essential Tremor? Clinics in Geriatric Medicine 36:1, 2020.  

Tevosian SG, Ghayee HK: Pheochromocytomas and Paragangliomas. Endocrinology and Metabolism Clinics of North America 48:4, 2019.  

Wong KS, Barletta JA: Thyroid Tumors You Don't Want to Miss., Surgical Pathology Clinics 12:4 2019.

Kliegman RM, Bordini BJ, Basel D, et al: How Doctors Think Common Diagnostic Errors in Clinical Judgment—Lessons from an Undiagnosed and Rare Disease Program. Pediatric Clinics of North America 64:1, 2020.

Youssef MJ, Chiu YE: Eczema and Urticaria as Manifestations of Undiagnosed and Rare Diseases. Pediatric Clinics of North America 64:1, 2020.

Kliegman RM, Bordini BJ, Basel D, et al: Undiagnosed and Rare Diseases in Perinatal Medicine: Lessons in Context and Cognitive Diagnostic Error. Clinics in Perinatology 47:1, 2020.  

Stolberg NG, Verbsky JW: Autoinflammatory Disorders with Perinatal Onset. Clinics in Perinatology 47:1, 2020.

Williams KB, Held PK, Schwoerer JS: Neonatal Metabolic Crises: A Practical Approach. Clinics in Perinatology 47:1, 2020.

Verbsky JW: When to Suspect Autoinflammatory/Recurrent Fever Syndromes. Pediatric Clinics of North America 64:1, 2017.

Routes JM, Verbsky JW: Immunodeficiency Presenting as an Undiagnosed Disease. Pediatric Clinics of North America 64:1 2017.

Notes for editors

1 What is Rare Disease Day?. EURORDIS (European Organization for Rare Diseases). https://www.rarediseaseday.org/article/about-rare-disease-day. Accessed January 27, 2020.

2 FAQ. NIH – GARD (Genetic and Rare Diseases Information Center) website https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases. Updated November 30, 2017

3 "Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database," by Wakap S.N., Lambert D.M., Alry A., et al. (https://doi.org/10.1038/s41431-019-0508-0). It appears European Journal of Human Genetics (September 2019), published by Springer Nature.

4 Navarro, C. Rare Diseases are not as Rare as They Seem. http://crosstalk.cell.com/blog/rare-diseases-arent-as-rare-as-they-seem. Published February 26, 2019.

5 About Rare Disease. Orphanet: the Portal for Rare Diseases and Orphan Drugs. https://www.orpha.net/consor/cgi-bin/Education_AboutRareDiseases.php?lng=EN. Updated January 26, 2020. Accessed January 27, 2020.

About Elsevier

Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we're committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com

Media contact

Christopher Capot, Global Communications
Elsevier
+1-917-704-5174
c.capot@elsevier.com

Logo: https://mma.prnewswire.com/media/754760/Elsevier_Logo.jpg

Modal title

Also from this source

Elsevier launches ScienceDirect AI to transform research with rapid mission-critical insights from trusted content

Elsevier launches ScienceDirect AI to transform research with rapid mission-critical insights from trusted content

Elsevier, a global leader in advanced information and decision support, today launches ScienceDirect AI, a cutting-edge generative AI tool for...

Elsevier Health launches HESI Clinical Practice Readiness Assessment (CPRA): the first assessment of its kind to assess nursing students' practice readiness

Elsevier Health launches HESI Clinical Practice Readiness Assessment (CPRA): the first assessment of its kind to assess nursing students' practice readiness

Elsevier Health, a global leader in medical information and data analytics, today launched HESI Clinical Practice Readiness Assessment (CPRA), the...

More Releases From This Source

Explore

Publishing & Information Services

Publishing & Information Services

STEM (Science, Tech, Engineering, Math)

STEM (Science, Tech, Engineering, Math)

Medical Pharmaceuticals

Medical Pharmaceuticals

Computer & Electronics

Computer & Electronics

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.